Form 8-K - Current report:
SEC Accession No. 0001493152-24-039218
Filing Date
2024-10-02
Accepted
2024-10-02 16:30:21
Documents
26
Period of Report
2024-10-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 63900
2 ex4-1.htm EX-4.1 118073
3 ex4-2.htm EX-4.2 151358
4 ex5-1.htm EX-5.1 26401
5 ex5-2.htm EX-5.2 16339
6 ex10-1.htm EX-10.1 776353
7 ex99-1.htm EX-99.1 15572
8 ex99-2.htm EX-99.2 14734
9 ex5-1_001.jpg GRAPHIC 14267
10 ex5-1_002.jpg GRAPHIC 25233
11 ex5-2_001.jpg GRAPHIC 5563
12 ex99-1_001.jpg GRAPHIC 1679
13 ex99-2_001.jpg GRAPHIC 4498
  Complete submission text file 0001493152-24-039218.txt   1723667

Data Files

Seq Description Document Type Size
14 XBRL SCHEMA FILE bctx-20241001.xsd EX-101.SCH 3750
15 XBRL DEFINITION FILE bctx-20241001_def.xml EX-101.DEF 29998
16 XBRL LABEL FILE bctx-20241001_lab.xml EX-101.LAB 36631
17 XBRL PRESENTATION FILE bctx-20241001_pre.xml EX-101.PRE 27021
29 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5668
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 241347892
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)